At the recent European Haematology Association (EHA) Annual Congress 2018, Myeloma Patients Europe (MPE) and Video Journal of Hematological Oncology (VJHemOnc), filmed an interview with Dr Michael Hudecek (University of Würzburg, Germany) on the Horizon2020 CARAMBA project.

MPE is collaborating with a consortium of European partners, including the University of Würzburg, on CARAMBA which is studying an innovative new treatment called chimeric antigen receptor T-cell (CAR-T) therapy in myeloma. In this video, Michael explains CAR-T cell therapy and the Horizon2020 CARAMBA project in more detail.

[embedyt] https://www.youtube.com/watch?v=C4eUG18BRjM[/embedyt]

In CAR-T, a type of white blood cell which makes up part of the immune system (T-cells) is collected from patients and equipped with the chimeric antigen receptor or “CAR”. When reintroduced into patients’ bodies, it acts like a sensor boosting the ability of the immune T-cells to find and destroy the myeloma cells. CARAMBA is running a Phase I/II clinical trial looking CAR-T cell therapy specifically targeting SLAMF7, a molecule expressed on the surface of myeloma cells.

For further information, please visit the Horizon2020 website: https://www.caramba-cart.eu/

Alternatively, please email info@mpeurope.org if you have any further questions about the project.